AIML Continues to Streamline for the Future and Moves Beyond Tech2Heal
Rhea-AI Summary
AI/ML Innovations Inc. (AIML) has announced its strategic exit from Tech2Heal SAS (T2H) through a formal agreement dated March 21, 2025. This decision follows a previously reported impairment loss of $1,510,668 from their T2H investment in October 2024.
Under the exit agreement, AIML will relinquish its 11.11% equity position in T2H, board seat rights, and AI RX Inc.'s exclusive North American product rights. In exchange, T2H will return 1,500,000 AIML common shares for cancellation and surrender its 30% equity in AI RX Inc. Additionally, T2H's CEO Fabrice Pakin will step down from both AIML and AI RX Inc.'s boards.
The company will now focus on commercializing its core holdings: NeuralCloud Solutions Inc., Health Gauge Inc. (95.2% owned), and Quantum Sciences . This restructuring aims to optimize the utilization of AIML's human, financial, and technological resources while remaining open to future collaborations with T2H.
AI-generated analysis. Not financial advice.
Positive
- Recovery of 1.5M common shares through cancellation
- Elimination of future capital requirements for Tech2Heal investment
- Streamlined focus on core profitable assets
Negative
- $1,510,668 impairment loss on Tech2Heal investment
- Loss of North American product rights and market presence
- Reduction in portfolio diversification
News Market Reaction – AIMLF
On the day this news was published, AIMLF declined 5.01%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AIML Sharpens Focus with Strategic Exit from Tech2Heal
Aligning Resources for Commercialization and Core Portfolio Growth
Transition Positions AIML to Prioritize Commercial Execution While Remaining Open to Future Collaboration
VANCOUVER, BC / ACCESS Newswire / March 21, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the execution of a formal exit agreement dated March 21, 2025 (the "Agreement") with Tech2Heal SAS ("T2H"), a France-based digital health company in which AIML previously held a minority interest.
On October 10, 2024, AIML reported an impairment loss of
Per the Agreement, AIML will relinquish: 1) its
Paul Duffy, CEO and Chairman of AIML, stated: "AIML remains committed to advancing digital health innovations that leverage artificial intelligence and machine learning. Looking ahead, this decision provides a clean transition and plenty of room for collaboration between our two organizations, particular with our ECG signal algorithm, while we maintain our focus on high-impact opportunities within our core portfolio. We appreciate T2H's contributions and look forward to potential collaborations in the future"
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.
About AI/ML Innovations Inc. https://aiml-innovations.com/
AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including with respect to the completion of the transactions proposed by the Agreement. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of AIML, including the timing and nature of all closing deliverables and whether the transactions contemplated by the Agreement will be completed as currently proposed or at all. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
SOURCE: AI/ML Innovations, Inc.
View the original press release on ACCESS Newswire